A MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMA
- Registry ID
- LY.17
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY
- Start date
- 2016-04-21
- Last update
- 2015-05-04
Conditions
- RELAPSED AND/OR REFRACTORY B-CELL LYMPHOMA
Related clinical trials
- A PHASE II, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE
OPTIMIZATION OF THE CYTOKINE RELEASE SYNDROME PROFILE FOR
GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS
OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE
LARGE B-CELL LYMPHOMA
- AN OPEN-LABEL, PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ENGLUMAFUSP ALFA (RO7227166, A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH OBINUTUZUMAB AND IN COMBINATION WITH GLOFITAMAB FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN¿S LYMPHOMA
- RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EPCORITAMAB PLUS LENALIDOMIDE COMPARED TO RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN
- EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING LISOCABTAGENE MARALEUCEL
THAT IS NONCONFORMING TO COMMERCIAL RELEASE
- A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-501A, AN ANTI-CD-19 ALLOGENEIC CAR T CELL THERAPY, AND ALLO-647, AN ANTI-CD52 MONOCLONAL ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (LBCL)
- A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION TRIAL OF GEN3013 IN PATIENTS WITH RELAPSED, PROGRESSIVE OR REFRACTORY B-CELL LYMPHOMA
View on source registry